COVID-19

Read about potential risks for COVID19 in patients with HM.
COVID-19, HARMONY PLUS
October 15, 2020

MPN 1: Exploring the Impact of Covid-19 on Outcomes in Myeloproliferative Neoplasms

Exploring the Impact of Covid-19 on Outcomes in Myeloproliferative ...
COVID-19, HARMONY PLUS, MPN
May 01, 2020

HARMONY
Healthcare Alliance for Resourceful Medicine Offensive against Neoplasms in Hematology

Funded through the Innovative Medicines Initiative (IMI) 2 Joint Undertaking and listed under grant agreement No. 116026. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

HARMONY Coordination Office
Institute of Biomedical Research of Salamanca (IBSAL)
Salamanca, Spain

harmonyoffice@ibsal.es
+34 678 841 121

HARMONY Communications
European Hematology Association (EHA)
The Hague
The Netherlands

communications@harmony-alliance.eu
+31 70 3020099